Our Research
Viral vector–based vaccine design uses harmless, engineered viruses to deliver genetic material encoding antigens from a target pathogen, thereby triggering a strong immune response. Such vaccines closely mimic natural infection, eliciting both antibody- and T cell–mediated immunity. They are versatile and effective against emerging diseases
Vaccine & Anti-Viral Development
Provides critical insights into how viruses recognize, bind, and penetrate host cells, revealing the molecular pathways they exploit. This knowledge not only advances our understanding of fundamental cell biology but also identifies potential therapeutic targets, aiding in the development of antivirals, monoclonal antibodies, and vaccines.
Virus-Host Interaction & Entry Mechanism
Virus discovery and evolution research has advanced from traditional methods to modern sequencing technologies, such as NGS, greatly enhancing our ability to identify novel and diverse pathogens in humans and animals. Studying how these viruses evolve and adapt provides essential insights into their diversity, origins, and potential impact on global health.
Virus Discovery & Evolution
Virus Discovery & Evolution
Monoclonal antibodies can neutralize viruses, block their entry, or modulate immune responses, making them powerful tools for both therapy and prevention. Their precision and adaptability also support vaccine design and diagnostic applications. We, at our lab, try to develop mAbs against ferret cytokines, which will serve for great diagnostic purposes.
Monoclonal Antibody Development
Zoonotic transmission refers to the spread of infectious diseases from animals to humans, often through direct contact, consumption, or environmental exposure. The majority of emerging infectious diseases in recent decades— including outbreaks caused by coronaviruses, influenza viruses, and flaviviruses— have originated from animal reservoirs.
Our laboratory is committed to advancing fundamental research on the molecular mechanisms that govern such zoonotic virus–host interactions, with a particular emphasis on the early stages of viral entry. Viral entry is a critical determinant of host range, tissue tropism, and pathogenesis, and understanding the molecular signaling pathways it engages is essential for identifying novel therapeutic and preventive strategies. To elucidate these mechanisms, we employ a broad toolkit of cell biology and microbiology approaches, including live-cell and confocal imaging to track viral entry and trafficking, biochemical assays to map protein–protein interactions, and next-generation sequencing to capture host transcriptional and signaling responses to infection. These complementary techniques allow us to dissect the spatiotemporal dynamics of virus–cell communication at a molecular level.
In parallel, our lab bridges this fundamental knowledge with translational research applications. We are actively developing monoclonal antibodies against host cytokines, both as tools for probing immune modulation during infection and as potential candidates for diagnostic applications. Furthermore, we are designing and validating nanoparticle-based vaccines against coronaviruses. Unlike conventional approaches targeting a single viral strain, our strategy focuses on eliciting immune responses that are cross-protective against multiple coronaviruses, thereby providing a platform for broad-spectrum protection and pandemic preparedness. By integrating mechanistic insights from molecular virology with applied innovations, our work aims to contribute to both a deeper scientific understanding of viral pathogenesis and the development of tangible solutions for public health.